- Home
- PSHG vs ELEV Comparison
PSHG vs ELEV Comparison
Compare PSHG & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- ELEV
- Stock Information
- Founded
- PSHG 2010
- ELEV 2019
- Country
- PSHG Greece
- ELEV United States
- Employees
- PSHG N/A
- ELEV N/A
- Industry
- PSHG Marine Transportation
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- ELEV Health Care
- Exchange
- PSHG Nasdaq
- ELEV Nasdaq
- Market Cap
- PSHG 20.1M
- ELEV 18.1M
- IPO Year
- PSHG N/A
- ELEV 2021
- Fundamental
- Price
- PSHG $1.63
- ELEV $0.32
- Analyst Decision
- PSHG Strong Buy
- ELEV Buy
- Analyst Count
- PSHG 1
- ELEV 6
- Target Price
- PSHG $6.50
- ELEV $2.94
- AVG Volume (30 Days)
- PSHG 59.2K
- ELEV 750.8K
- Earning Date
- PSHG 07-24-2025
- ELEV 08-05-2025
- Dividend Yield
- PSHG N/A
- ELEV N/A
- EPS Growth
- PSHG N/A
- ELEV N/A
- EPS
- PSHG 1.58
- ELEV N/A
- Revenue
- PSHG $86,407,000.00
- ELEV N/A
- Revenue This Year
- PSHG N/A
- ELEV N/A
- Revenue Next Year
- PSHG $21.44
- ELEV N/A
- P/E Ratio
- PSHG $1.03
- ELEV N/A
- Revenue Growth
- PSHG N/A
- ELEV N/A
- 52 Week Low
- PSHG $1.31
- ELEV $0.22
- 52 Week High
- PSHG $2.34
- ELEV $3.77
- Technical
- Relative Strength Index (RSI)
- PSHG 56.29
- ELEV 49.38
- Support Level
- PSHG $1.58
- ELEV $0.29
- Resistance Level
- PSHG $1.73
- ELEV $0.32
- Average True Range (ATR)
- PSHG 0.10
- ELEV 0.02
- MACD
- PSHG 0.01
- ELEV 0.00
- Stochastic Oscillator
- PSHG 61.11
- ELEV 59.01
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.